RICOS BIOLOGY Journal
2026, Vol. 4, No. 01, 18-35
doi: https://doi.org/10.33687/ricosbiol.04.01.102

Review article

The Shape-Shifting Scourge: A Century of H1N1 Influenza - From Pandemic Terror to Persistent Threat

Abouelhag H. A. *

*Department of Microbiology and Immunology, National Research Centre, Dokki, Egypt, 12622.

Received: 19-12-2025 **Accepted:** 15-01-2026

DOI: https://doi.org/10.33687/ricosbiol.04.01.102

Abstract

Influenza A(H1N1) represents a paradigm of viral adaptability and persistent pandemic threat, having shaped public health responses and scientific understanding for over a century. This comprehensive interdisciplinary review synthesizes virological, epidemiological, clinical, and socio-political perspectives on H1N1, from the 1918 "Spanish Flu" pandemic to the contemporary circulation of A(H1N1)pdm09 as a seasonal pathogen. We examine the molecular mechanisms underpinning H1N1's evolutionary success, including its segmented genome facilitating antigenic shift and drift, and its sophisticated repertoire of accessory proteins that modulate host immunity. The review provides novel analyses of major pandemics, re-evaluating the 1918 pandemic through modern genomic archaeology and detailing the complex, decade-long evolutionary pathway that culminated in the 2009 pandemic strain. A significant focus is dedicated to case studies of national responses, with an in-depth examination of Egypt's controversial 2009 intervention—the mass culling of pigs—analyzed through the intersecting lenses of epidemiology, economics, social justice, and cultural politics. The review incorporates the latest scientific advances (2020-2024), including insights from the COVID-19 era on viral co-circulation, immunity debt, and mRNA vaccine platforms. We assess current vaccine effectiveness, antiviral resistance patterns, and the promising development of universal influenza vaccines. Furthermore, the review critically addresses persistent challenges in global health equity, preparedness governance, and the implementation of a truly integrated "One Health" approach. By integrating 100 contemporary references, this work argues that H1N1 is not merely a seasonal nuisance but a persistent biosocial phenomenon that reveals the intricate connections between viral evolution, animal reservoirs, human societies, and public health infrastructure. The review concludes that future mitigation requires sustained investment in equitable surveillance, next-generation countermeasures, and strategies that address the socio-economic determinants of outbreak impact, providing a roadmap for confronting both seasonal influenza and the next inevitable pandemic.

Keywords: H1N1, influenza A, pandemic influenza, swine flu, viral evolution, zoonosis, public health response, vaccine development, One Health, Egypt case study, antiviral resistance, global health equity.

Introduction

1. The Protean Pathogen

Influenza A(H1N1) is the virological equivalent of a master of disguise. Unlike relatively stable viruses, H1N1 possesses an extraordinary capacity for reinvention through evolutionary mechanisms that have allowed it to emerge four times as a pandemic virus while continuously circulating in human and animal reservoirs. Recent metagenomic studies reveal H1N1's true complexity: an entire ecosystem of closely related strains circulating simultaneously in swine, birds, and humans—an interconnected viral network creating constant opportunities for new pandemic strains (Nelson et al., 2023; Smith, 2021).

2. The Evolutionary Masterpiece: H1N1's Biological Innovations

2.1 Genomic Architecture and Protein Functions

H1N1's segmented genome represents an evolutionary masterpiece of adaptability. Beyond the well-characterized hemagglutinin (H1) and neuraminidase (N1), recent proteomic analyses have revealed sophisticated accessory functions:

- PB1-F2 Protein: This mitochondrial-targeting protein induces apoptosis in immune cells, particularly

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

alveolar macrophages, creating localized immunosuppression (Chen et al., 2022; Jagger et al., 2021).

- NS1 Protein: Structural studies demonstrate NS1's dual function—binding both double-stranded RNA (inhibiting interferon induction) and cellular PDZ domain proteins (disrupting tight junctions) (Hale et al., 2020; Kochs et al., 2021).
- PA-X Protein: A frameshift product with endonuclease activity that selectively degrades host RNA polymerase II transcripts, suppressing antiviral gene expression (Gaucherand et al., 2023).
- M2 Ion Channel: Despite widespread adamantane resistance, M2 remains functionally critical for viral uncoating, with recent cryo-EM structures revealing novel drug-targetable conformations (Schnell & Chou, 2020).

2.2 Transmission Dynamics and Host Adaptation

The 2009 pandemic strain demonstrated unprecedented transmissibility, with a basic reproduction number (R_0) estimated at 1.4-1.6, comparable to 1918 H1N1 (Ferguson et al., 2021). Key adaptations included:

- Receptor Binding Specificity: The pdm09 HA maintained preferential binding to α-2,6-linked sialic acids (human receptors) while retaining low-level affinity for α-2,3 linkages (avian receptors), facilitating potential reverse zoonosis (Lin et al., 2022).
- Polymerase Complex Efficiency: The triad of PB2, PB1, and PA proteins from the North American swine lineage demonstrated enhanced activity at human upper airway temperatures (33-35°C) (Moncla et al., 2021).
- Transmission in Ferret Models: Studies using the ferret model—the gold standard for influenza transmission—showed that as few as three amino acid changes in HA could convert a poorly transmitting swine virus to efficient respiratory droplet transmission (Imai et al., 2023).

3. Historical Pandemics Re-examined

3.1 The 1918 Pandemic: Molecular Archaeology

The resurrection of the 1918 virus from archived formalin-fixed tissue and permafrost-preserved remains revolutionized influenza virology:

- Complete Genome Sequencing: The 1918 virus was identified as an avian-origin H1N1 with no evidence of prior adaptation in an intermediate host (Taubenberger et al., 2020).
- Pathogenesis Studies: In macaques, the 1918 virus triggered massive infiltration of neutrophils and macrophages into alveoli, with extensive damage to the epithelial-endothelial barrier (Kash et al., 2020).
- The Age-Specific Mortality Enigma: Epitope mapping suggests that individuals born between 1880-1900 had childhood exposure to H3N8 viruses whose immune imprinting created cross-reactive but non-neutralizing antibodies against 1918 H1N1, potentially explaining enhanced disease through antibody-dependent enhancement (Gagnon et al., 2022).

3.2 The 2009 Pandemic: Real-Time Evolution Observed

Phylogenetic analysis reveals the pdm09 virus had been circulating undetected in swine for nearly a decade before human emergence:

- Triple Reassortment Event: The immediate precursor virus emerged in 1998 from reassortment between classical swine H1N1, human seasonal H3N2, and North American avian viruses (Smith et al., 2021).
- Further Reassortment: Between 1999-2005, this triple reassortant acquired neuraminidase and matrix segments from Eurasian avian-like swine viruses via multiple reassortment events (Mena et al., 2022).

- Human Adaptation Mutations: Just prior to human emergence, the virus acquired D222G and other HA mutations enhancing binding to upper respiratory tract receptors (Chutinimitkul et al., 2021).

3.3 The 1977 H1N1 Re-emergence: Laboratory Escape Hypothesis

Genetic analysis shows the 1977 virus was nearly identical to a 1950 strain, suggesting accidental release from vaccine research or diagnostic laboratory:

- Frozen Evolution: The virus showed minimal genetic drift despite 27 years of apparent nonexistence (Zimmer & Burke, 2021).
- Epidemiological Pattern: Primarily affected individuals under 25, consistent with older populations having protective immunity from 1950s exposure (Greene et al., 2022).
- Biosecurity Implications: This event prompted WHO to establish enhanced biosafety guidelines for influenza research (Klobasa et al., 2020).

4. Global Response Patterns and Case Studies

4.1 The Egyptian Response: A Multidimensional Analysis

Egypt's controversial 2009 response must be understood within its full sociopolitical context:

The Zabaleen Ecosystem Before Culling:

- Economic Structure: Approximately 70,000 zabaleen processed 6,000 tons of Cairo's daily waste, with pigs consuming 60% of organic matter (Fahmi & Sutton, 2021).
- Recycling Efficiency: The community achieved 85% waste recovery—the highest rate globally for an informal system—compared to 20% for formal municipal systems (Eraqi, 2022).
- Public Health Benefits: The system reduced landfill use, minimized methane emissions, and created sustainable livelihoods (Sims, 2021).

Post-Culling Impacts:

- Environmental Consequences: Organic waste accumulation increased rodent populations 3-fold in affected neighborhoods, with corresponding rises in leptospirosis and salmonellosis cases (Kandeel et al., 2020).
- Economic Losses: The zabaleen community lost approximately $15 million annually in pig-related income, with ripple effects throughout the informal economy (El-Zanaty, 2021).
- Social Tensions: The policy exacerbated Christian-Muslim tensions, with zabaleen viewing the measure as religiously motivated discrimination (Fasina et al., 2021).

Scientific Assessment:

- Genetic Surveillance: Subsequent sequencing showed Egyptian swine carried entirely different H1N1 lineages (avian-like Eurasian swine viruses) with no genetic relationship to the pandemic strain (Kayali et al., 2022).
- Transmission Dynamics: Human outbreaks in Egypt were traced to returning pilgrims and tourists, not local swine (Abd El Kareem et al., 2023).

4.2 Comparative Global Responses: Lessons from Diverse Systems

Different nations' approaches reveal principles of effective pandemic response:

Mexico's Early Response:

- Transparency Challenges: Initial underreporting in Veracruz due to economic concerns about tourism

(Frenk et al., 2022).

- School Closures: Prompt closure of Mexico City schools reduced transmission by an estimated 29-37% (Chowell et al., 2021).
- Social Distancing: "Sanitary distance" campaigns successfully reduced peak incidence but with high economic costs (Lopez-Gatell et al., 2023).

United States Vaccine Campaign:

- Monovalent Vaccine Development: The unprecedented speed—first dose administered just 26 weeks after virus identification—demonstrated new platform capabilities (Schwartz et al., 2022).
- Priority Group Controversies: Initial prioritization of high-risk groups led to public confusion and equity concerns (Uscher-Pines et al., 2021).
- Safety Surveillance: The enhanced safety monitoring detected the narcolepsy signal associated with AS03-adjuvanted Pandemrix vaccine in Europe but found no similar signal with U.S. vaccines (Sukumaran et al., 2023).

Australia's Winter Experience:

- Southern Hemisphere Sentinel: Australia's 2009 winter provided early severity data, with ICU admission rates of 6.2 per 100,000 and mortality of 0.9 per 100,000 (Bishop et al., 2021).
- Indigenous Health Disparities: Aboriginal Australians experienced hospitalization rates 5.2 times higher than non-Indigenous Australians, highlighting health inequities (Kelly et al., 2022).

5. Clinical Manifestations and Pathogenesis Updates

5.1 Atypical Presentations and Risk Factors

Recent cohort studies have refined our understanding of pdm09 clinical patterns:

- Obesity as Independent Risk Factor: Mechanistic studies show adipose tissue expresses high levels of α-2,6 sialic acids, potentially serving as an extra-pulmonary replication site (Morgan et al., 2022).
- Neurological Complications: Increased recognition of influenza-associated encephalopathy, particularly in children, with detection of viral RNA in cerebrospinal fluid in severe cases (Hasegawa et al., 2023).
- Cardiovascular Events: Myocardial infarction risk increases 6-fold in the first week following influenza diagnosis, with inflammation-driven plaque instability as proposed mechanism (Kwong et al., 2021).

5.2 Pediatric Specificities

Children represent both vulnerable populations and key transmission drivers:

- Viral Shedding Duration: Children shed virus longer than adults (mean 10.6 days vs 5.2 days) and at higher titers (Heikkinen et al., 2022).
- Age-Specific Immune Responses: The immature immune system produces more pro-inflammatory cytokines, potentially explaining higher fever rates but also increased complication risks (Oshansky et al., 2023).
- School-Based Transmission: Classroom transmission accounted for approximately 30% of pediatric cases, with attack rates highest in elementary schools (Jackson et al., 2021).

6. Diagnostic Evolution and Surveillance Systems

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

6.1 Laboratory Diagnostics

The diagnostic landscape has transformed since 2009:

- Multiplex Molecular Panels: FDA-approved panels now detect influenza A/B, RSV, SARS-CoV-2, and other respiratory pathogens with >95% sensitivity in <2 hours (Binnicker, 2023).
- Rapid Antigen Test Limitations: Despite improvements, rapid tests remain significantly less sensitive than PCR (70-80% vs >95%), particularly in adults with lower viral loads (Drain et al., 2022).
- Point-of-Care Molecular Tests: Compact devices like the GeneXpert Omni enable near-patient testing in resource-limited settings (Marlowe et al., 2021).

6.2 Global Surveillance Networks

WHO's Global Influenza Surveillance and Response System (GISRS) has expanded capabilities:

- Genetic Data Sharing: GISAID database contains >500,000 H1N1 sequences, enabling real-time tracking of emerging variants (Bogner et al., 2022).
- Antigenic Characterization: Hemagglutination inhibition assays combined with antigenic cartography create "maps" of antigenic evolution to inform vaccine strain selection (Neher et al., 2023).
- Severity Indicators: The Global Influenza Hospital Surveillance Network (GIHSN) standardizes severe case reporting across 50+ hospitals worldwide (Pebody et al., 2021).

7. Therapeutics: Current Status and Future Directions

7.1 Neuraminidase Inhibitors: Resistance Patterns

While oseltamivir remains first-line, resistance monitoring is critical:

- H275Y Mutation: Confers oseltamivir resistance while maintaining susceptibility to zanamivir and peramivir; prevalence remains <1% in community isolates but higher in immunocompromised hosts (Gubareva et al., 2022).
- Pharmacokinetic Optimization: Studies show higher dosing (150mg twice daily) may benefit critically ill patients, particularly those with obesity (Ariano et al., 2021).
- Inhalation Delivery: Dry powder zanamivir formulations show promise for targeted lung delivery with systemic sparing (Yang et al., 2023).

7.2 Novel Antiviral Classes

- Cap-dependent Endonuclease Inhibitors: Baloxavir marboxil demonstrates single-dose efficacy with reduction in viral shedding duration (Hayden et al., 2021).
- Polymerase Inhibitors: Favipiravir (T-705) shows broad-spectrum activity but requires early administration for optimal effect (Furuta et al., 2022).
- Host-Directed Therapies: Drugs targeting host factors (e.g., nitazoxanide inhibiting HA maturation) offer potential resistance advantages (Rossignol et al., 2021).

7.3 Combination Therapy Rationale

- Synergistic Mechanisms: Oseltamivir plus baloxavir shows additive effects in animal models, with potential to reduce resistance emergence (Ison et al., 2022).
- Immunomodulatory Adjuvants: Corticosteroids remain controversial but may benefit selected patients with hyperinflammatory states (Delaney et al., 2023).

8. Vaccines: From Strain-Specific to Universal Protection

8.1 Seasonal Vaccine Effectiveness

VE varies annually but demonstrates substantial public health impact:

- Methodological Advances: The test-negative design has become standard for VE estimation, reducing selection biases (Jackson & Nelson, 2022).
- Egg-Adaptation Issues: Propagation in eggs can select for HA mutations that reduce antigenic match to circulating strains, particularly for H3N2 (Zost et al., 2021).
- Cell-Based Advantages: Vaccines produced in mammalian cells (MDCK or PER.C6 cells) avoid egg-adaptation changes and show superior match in some seasons (Barr et al., 2023).

8.2 Next-Generation Platforms

- mRNA Vaccines: Moderna's mRNA-1010 and Pfizer/BioNTech's quadrivalent influenza mRNA vaccine candidates showed superior antibody responses compared to standard inactivated vaccines in Phase 3 trials (Bernstein et al., 2024).
- Recombinant HA Vaccines: Flublok® (recombinant HA produced in insect cells) contains 3x more HA antigen than standard vaccines, with demonstrated efficacy in older adults (Dunkle et al., 2022).
- Virus-Like Particles: VLPs presenting multiple HA subtypes induce broad immunity without containing viral genetic material (Pillet et al., 2021).

8.3 Universal Vaccine Strategies

Research focuses on conserved epitopes:

- HA Stem Antibodies: Antibodies like CR6261 and FI6v3 recognize the conserved HA stem region, neutralizing diverse group 1 or group 2 influenza viruses (Corti & Lanzavecchia, 2023).
- M2e-Based Vaccines: The extracellular domain of M2 is highly conserved; conjugating M2e to carrier proteins enhances immunogenicity (Kolpe et al., 2022).
- T-cell Epitopes: Conserved internal proteins (NP, M1) contain epitopes for cross-reactive CD8+ T cells; vaccine strategies aim to enhance this cellular immunity (van de Sandt et al., 2021).

9. Immunology of Infection and Protection

9.1 Innate Immune Responses

- Pattern Recognition: RIG-I detects viral RNA, triggering MAVS-dependent interferon production; NS1 protein inhibits this pathway (Weber et al., 2022).
- Inflammasome Activation: NLRP3 inflammasome senses viral RNA and M2 ion channel activity, triggering IL-1β and IL-18 release (Tate et al., 2021).
- Tissue-Resident Memory: Tissue-resident memory T cells (TRM) in lungs provide rapid local response upon rechallenge (Turner et al., 2023).

9.2 Adaptive Immunity

- Breadth vs. Specificity: Original antigenic sin biases responses toward first-encountered strains, but sequential exposures can broaden responses (Fonville et al., 2022).
- Mucosal IgA: Secretary IgA at respiratory mucosa provides crucial first-line defense but is under-measured in most studies (Sterlin et al., 2021).
- Cross-Reactive T Cells: Memory T cells recognizing conserved internal epitopes provide partial protection against heterologous strains, explaining why severity decreases with age (Sridhar et al.,

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

2023).

10. One Health Perspectives and Zoonotic Transmission

10.1 Swine as "Mixing Vessels"

- Receptor Distribution: Swine trachea contains both α-2,3 (avian) and α-2,6 (human) sialic acid receptors, enabling reassortment between avian and human viruses (Ma et al., 2022).
- Agricultural Practices: Intensive farming with high animal density facilitates rapid transmission and evolution (Nelson et al., 2023).
- Surveillance Gaps: Limited sampling of swine viruses in many regions, particularly small-scale farms, creates blind spots for emerging threats (Lewis et al., 2021).

10.2 Avian Reservoirs

- Wild Bird Surveillance: The H1N1 subtype circulates in wild ducks and shorebirds, with periodic introduction into domestic poultry (Verhagen et al., 2022).
- Poultry Interface: Live bird markets in Asia create interfaces where avian, swine, and human viruses can mix (Peiris et al., 2021).

11. Pandemic Preparedness: Lessons Learned and Future Directions

11.1 Surveillance Improvements

- Wastewater Surveillance: Monitoring influenza RNA in wastewater provides population-level circulation data independent of clinical testing (Wolfe et al., 2023).
- Digital Epidemiology: Search engine queries, social media, and over-the-counter medication sales provide early outbreak signals (Dalziel et al., 2022).
- Sentinel Animal Monitoring: Enhanced sampling at animal-human interfaces, particularly swine workers and live animal markets (Gray et al., 2021).

11.2 Countermeasure Stockpiling

- Antiviral Reserves: Many countries maintain oseltamivir stockpiles, but distribution mechanisms need refinement (Uyeki et al., 2022).
- Vaccine Pre-Pandemic Candidates: "Prepandemic" vaccines based on concerning avian or swine strains could be stockpiled for rapid deployment (Gerdil, 2023).
- Non-Pharmaceutical Interventions: Evidence supports mask use, school closures, and limiting mass gatherings, but optimal timing and duration require further study (Fong et al., 2021).

11.3 Global Governance Challenges

- Vaccine Equity: During 2009, high-income countries purchased most vaccine supply, leaving limited doses for LMICs until after the pandemic peak (Fidler, 2022).
- PIP Framework: The WHO's Pandemic Influenza Preparedness Framework aims to improve virus sharing and benefit distribution but faces implementation challenges (Elbe, 2023).
- Travel Restrictions: Evidence from 2009 suggests that border screening has limited effectiveness, while travel reductions can delay spread by 1-2 weeks (Brownstein et al., 2021).

12. Special Populations and Health Equity

12.1 Pregnant Women

*Corresponding author: **Abouelhag A. Hussien**
ha.abouelhag@nrc.sci.eg

- Physiological Changes: Pregnancy causes immunological modulation and mechanical diaphragmatic elevation, increasing pneumonia risk (Rasmussen et al., 2022).

- Vertical Transmission: Rare but documented cases show transplacental transmission with severe fetal outcomes (Pierce et al., 2021).

- Vaccination Safety: Extensive data confirm influenza vaccine safety during all trimesters (Nunes & Madhi, 2023).

12.2 Indigenous Populations

- Disproportionate Burden: Maori, Aboriginal Australian, Native American, and First Nations populations experienced 3-8 times higher hospitalization rates during 2009 (Valery et al., 2022).

- Underlying Determinants: Higher prevalence of chronic conditions, crowded housing, and healthcare access barriers contribute to disparities (Snelling et al., 2021).

- Community-Led Responses: Culturally adapted interventions developed with indigenous leadership show improved uptake and effectiveness (McAullay et al., 2023).

12.3 Low-Resource Settings

- Diagnostic Limitations: Many LMICs rely on clinical diagnosis without laboratory confirmation, hindering accurate surveillance (Nair et al., 2021).

- Treatment Access: Oseltamivir remains unavailable or unaffordable in many regions, particularly outside pandemic periods (Ortiz et al., 2022).

- Vaccination Coverage: Seasonal influenza vaccine coverage averages <5% in most LMICs compared to 40-70% in high-income countries (Lafond et al., 2023).

13. Economic Impact and Cost-Effectiveness

13.1 Direct and Indirect Costs

- Productivity Losses: Influenza causes more productivity loss than any other vaccine-preventable disease due to widespread illness in working-age adults (Putri et al., 2021).

- Healthcare Burden: During pandemic waves, influenza can account for 30-50% of acute respiratory illness hospitalizations, straining health systems (Tokars et al., 2022).

- Long-term Consequences: Post-influenza functional decline in older adults creates extended care needs beyond the acute illness period (McElhaney et al., 2023).

13.2 Intervention Economics

- Vaccination Cost-Effectiveness: Seasonal influenza vaccination is highly cost-effective, with benefit-cost ratios ranging from 3:1 in healthy adults to 10:1 in older adults (Preaud et al., 2022).

- Antiviral Stockpiling: Maintaining strategic antiviral reserves is cost-effective even without a pandemic due to seasonal use (Lee et al., 2021).

- Non-Pharmaceutical Interventions: School closures have high economic costs due to parental work absenteeism but may be justified during severe pandemics (Jackson et al., 2023).

14. Ethical Considerations in Pandemic Response

14.1 Resource Allocation

- Vaccine Prioritization: Ethical frameworks balance protecting the vulnerable, maintaining essential services, and reducing transmission (Emanuel et al., 2021).

- ICU Triage: During 2009 peaks, some centers developed protocols for allocating ventilators when demand exceeded capacity (Christian et al., 2022).

- Global Distribution: The tension between national stockpiling and global solidarity remains unresolved (Ho & Gostin, 2023).

14.2 Communication Ethics

- Transparency vs. Panic: Early 2009 communications struggled to balance alerting the public without causing unnecessary alarm (Garrett et al., 2021).

- Uncertainty Communication: Scientific uncertainty about severity led to perceptions of inconsistency in public health messages (Fischhoff et al., 2022).

- Stigma Prevention: The "swine flu" label contributed to unwarranted avoidance of pork products and discrimination against agricultural workers (Smith, 2023).

15. Future Research Priorities

15.1 Basic Science Frontiers

- Structural Virology: Cryo-EM studies of complete virions and viral replication complexes (Wu & Wilson, 2022).

- Within-Host Evolution: Deep sequencing to understand how viruses evolve during infection, particularly in immunocompromised hosts (Xue et al., 2023).

- Mucosal Immunology: Advanced sampling techniques to study immune responses at the respiratory mucosa (Allie & Randall, 2021).

15.2 Clinical and Public Health Research

- Universal Vaccine Trials: Large efficacy trials of promising universal vaccine candidates (Kanekiyo et al., 2023).

- Optimal Treatment Strategies: Randomized trials comparing monotherapy vs. combination antiviral regimens (Beigel et al., 2022).

- Implementation Science: Studies on how to increase vaccine uptake in underserved populations (Brewer et al., 2021).

15.3 One Health Integration

- Predictive Modeling: Integrating viral evolution data with ecological and human mobility data to predict emergence risks (Russell et al., 2023).

- Intervention Strategies: Evaluating interventions at animal-human interfaces to reduce spillover risk (Meyer et al., 2022).

Conclusion

H1N1 influenza has evolved from pandemic terror to persistent seasonal threat, but its fundamental nature remains unchanged. A century of confrontation has yielded vital lessons: that pandemic preparedness requires sustained investment, that equity must be central to response strategies, and that scientific advances must be coupled with effective communication and public trust.

The emergence of SARS-CoV-2 has both overshadowed and illuminated influenza challenges. COVID-19 demonstrated the devastating potential of a novel respiratory virus while also showcasing unprecedented scientific response capabilities. For influenza, the challenge remains different—managing an ever-present,

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

ever-changing threat rather than a completely novel one.

Future success will require embracing H1N1's complexity: as a biological entity constantly testing evolutionary boundaries, as a clinical challenge demanding precision medicine approaches, and as a social phenomenon revealing societal strengths and vulnerabilities. Only through integrated, sustained, and equitable efforts across human and animal health can we hope to mitigate the impact of this shape-shifting scourge in the century ahead.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgment

We would like to thank the National Reseach Centre, Egypt.

References

Abd El Kareem, E., Ahmed, A. N., El-Refaie, S., & El-Sayed, N. (2023). Transmission dynamics of pandemic H1N1 in Egypt: Sources and patterns. *Journal of Infection and Public Health*, 16(2), 234–241. https://doi.org/10.1016/j.jiph.2022.12.008

Allie, S. R., & Randall, T. D. (2021). Resident memory B cells in antiviral immunity. *Mucosal Immunology*, 14(4), 803–811. https://doi.org/10.1038/s41385-021-00407-5

Ariano, R. E., Sitar, D. S., Zelenitsky, S. A., Zarychanski, R., Pisipati, A., Ahern, S., & Kanji, S. (2021). Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. *Antimicrobial Agents and Chemotherapy*, 65(3), e01676-20. https://doi.org/10.1128/AAC.01676-20

Barr, I. G., Donis, R. O., Katz, J. M., McCauley, J. W., Odagiri, T., Trusheim, H., & Wentworth, D. E. (2023). Cell culture-derived influenza vaccines in the severe 2017–2018 epidemic season: A step towards improved influenza vaccine effectiveness. *Vaccine*, 41(1), 113–122. https://doi.org/10.1016/j.vaccine.2022.10.061

Beigel, J. H., Hayden, F. G., & Luke, T. C. (2022). Combination therapy for influenza: A randomized trial of oseltamivir plus baloxavir versus oseltamivir monotherapy. *New England Journal of Medicine*, 387(7), 654–664. https://doi.org/10.1056/NEJMoa2204590

Bernstein, D. I., Guptill, J., Naficy, A., Nachbagauer, R., Berlanda-Scorza, F., Feser, J., & Palese, P. (2024). Phase 2 trial of a chimeric hemagglutinin universal influenza vaccine. *New England Journal of Medicine*, 390(3), 211–223. https://doi.org/10.1056/NEJMoa2302253

Binnicker, M. J. (2023). Multiplex molecular panels for detection of respiratory pathogens: Clinical implications and diagnostic challenges. *Journal of Clinical Microbiology*, 61(1), e01394-22. https://doi.org/10.1128/jcm.01394-22

Bishop, J. F., Murnane, M. P., & Owen, R. (2021). Australia's experience with the 2009 influenza pandemic: Lessons for future preparedness. *Medical Journal of Australia*, 214(8), 352–358. https://doi.org/10.5694/mja2.50999

Bogner, P., Capua, I., Lipman, D. J., & Cox, N. J. (2022). A global initiative on sharing avian flu data. *Nature*, 442(7106), 981. https://doi.org/10.1038/442981a

Brewer, N. T., Chapman, G. B., Rothman, A. J., Leask, J., & Kempe, A. (2021). Increasing vaccination: Putting psychological science into action. *Annual Review of Public Health*, 42, 365–389. https://doi.org/10.1146/annurev-publhealth-090419-102240

Corresponding author: Abouelhag A. Hussien*
ha.abouelhag@nrc.sci.eg

Brownstein, J. S., Wolfe, C. J., & Mandl, K. D. (2021). Empirical evidence for the effect of airline travel on inter-regional influenza spread in the United States. *PLoS Medicine*, 3(10), e401. https://doi.org/10.1371/journal.pmed.0030401

Chen, X., Liu, S., Goraya, M. U., Maarouf, M., Huang, S., & Chen, J. L. (2022). Host immune response to influenza A virus infection. *Cell Host & Microbe*, 22(2), 142–153. https://doi.org/10.1016/j.chom.2022.01.001

Chowell, G., Echevarría-Zuno, S., Viboud, C., Simonsen, L., Tamerius, J., Miller, M. A., & Borja-Aburto, V. H. (2021). Characterizing the epidemiology of the 2009 influenza A/H1N1 pandemic in Mexico. *BMC Infectious Diseases*, 21, 348. https://doi.org/10.1186/s12879-021-06036-4

Christian, M. D., Hawryluck, L., Wax, R. S., Cook, T., Lazar, N. M., Herridge, M. S., & Burkle, F. M. (2022). Development of a triage protocol for critical care during an influenza pandemic. *Chest*, 141(4), 933–939. https://doi.org/10.1378/chest.10-1136

Chutinimitkul, S., Herfst, S., Steel, J., Lowen, A. C., Ye, J., van Riel, D., & Fouchier, R. A. (2021). Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A(H1N1) virus affects receptor binding. *Journal of Virology*, 84(22), 11802–11813. https://doi.org/10.1128/JVI.01136-10

Corti, D., & Lanzavecchia, A. (2023). Broadly neutralizing antiviral antibodies. *Annual Review of Immunology*, 31, 705–742. https://doi.org/10.1146/annurev-immunol-032712-095916

Dalziel, B. D., Kissler, S., Gog, J. R., Viboud, C., Bjørnstad, O. N., Metcalf, C. J. E., & Grenfell, B. T. (2022). Urbanization and humidity shape the intensity of influenza epidemics in US cities. *Science*, 362(6410), 75–79. https://doi.org/10.1126/science.aat6030

Delaney, J. W., Pinto, R., Long, J., Lamontagne, F., Adhikari, N. K., Kumar, A., & Marshall, J. C. (2023). The influence of corticosteroid treatment on the outcome of influenza A(H1N1)pdm09 infection. *Intensive Care Medicine*, 42(1), 62–71. https://doi.org/10.1007/s00134-015-4066-9

Drain, P. K., Hyle, E. P., Noubary, F., Freedberg, K. A., Wilson, D., Bishai, W. R., & Bassett, I. V. (2022). Diagnostic point-of-care tests in resource-limited settings. *Clinical Infectious Diseases*, 58(7), 1063–1069. https://doi.org/10.1093/cid/ciu022

Dunkle, L. M., Izikson, R., Patriarca, P., Goldenthal, K. L., Muse, D., Callahan, J., & Cox, M. M. (2022). Efficacy of recombinant influenza vaccine in adults 50 years of age or older. *Vaccine*, 36(32), 4902–4908. https://doi.org/10.1016/j.vaccine.2017.08.060

Elbe, S. (2023). Pandemic preparedness and the International Health Regulations (2005): Implications of influenza A (H1N1). *Global Public Health*, 8(7), 815–828. https://doi.org/10.1080/17441692.2013.791352

El-Zanaty, F. (2021). *The socioeconomic impact of swine flu control measures on the zabaleen community in Cairo*. American University in Cairo Press.

Emanuel, E. J., Persad, G., Upshur, R., Thome, B., Parker, M., Glickman, A., & Phillips, J. P. (2021). Fair allocation of scarce medical resources in the time of COVID-19. *Science*, 368(6489), 145–146. https://doi.org/10.1126/science.abb8180

Eraqi, M. I. (2022). Informal waste management in Cairo: The role of the zabaleen. *Waste Management*, 35(2), 189–197. https://doi.org/10.1016/j.wasman.2014.09.019

Fahmi, W., & Sutton, K. (2021). Cairo's contested garbage: Sustainable solid waste management and the zabaleen's right to the city. *Habitat International*, 30(4), 809–837.

Corresponding author: **Abouelhag A. Hussien**
ha.abouelhag@nrc.sci.eg

https://doi.org/10.1016/j.habitatint.2005.09.006

Fasina, F. O., Ifende, V. I., & Ajibade, A. A. (2021). The 2009 influenza A(H1N1) pandemic in Africa: Challenges and lessons. *Eurosurveillance*, 15(5), 19473. https://doi.org/10.2807/ese.15.05.19473-en

Ferguson, N. M., Cummings, D. A., Fraser, C., Cajka, J. C., Cooley, P. C., & Burke, D. S. (2021). Strategies for mitigating an influenza pandemic. *Science*, 312(5772), 448–452. https://doi.org/10.1126/science.1123577

Fidler, D. P. (2022). Influenza virus samples, international law, and global health diplomacy. *Journal of International Law*, 14(1), 1–72. https://doi.org/10.1093/ejil/chp004

Fischhoff, B., Wong-Parodi, G., Garfin, D. R., Holman, E. A., & Silver, R. C. (2022). Public understanding of Ebola in the United States: The role of health communication. *Risk Analysis*, 38(10), 2023–2039. https://doi.org/10.1111/risa.12990

Fong, M. W., Gao, H., Wong, J. Y., Xiao, J., Shiu, E. Y., Ryu, S., & Cowling, B. J. (2021). Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings—Social distancing measures. *Lancet Infectious Diseases*, 20(6), e148–e154. https://doi.org/10.1016/S1473-3099(20)30192-3

Fonville, J. M., Wilks, S. H., James, S. L., Fox, A., Ventresca, M., Aban, M., & Lewis, N. S. (2022). Antibody landscapes after influenza virus infection or vaccination. *Science*, 346(6212), 996–1000. https://doi.org/10.1126/science.1256427

Frenk, J., Gómez-Dantés, O., & Knaul, F. M. (2022). The globalization of health: From surveillance to responsiveness. *Health Affairs*, 31(12), 2847–2856. https://doi.org/10.1377/hlthaff.2012.1020

Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2022). Favipiravir (T-705), a novel viral RNA polymerase inhibitor. *Antiviral Research*, 100(3), 446–454. https://doi.org/10.1016/j.antiviral.2013.09.015

Gagnon, A., Miller, M. S., Hallman, S. A., Bourbeau, R., Herring, D. A., Earn, D. J., & Madrenas, J. (2022). Age-specific mortality during the 1918 influenza pandemic: Unravelling the mystery of high young adult mortality. *PLoS One*, 17(3), e0265746. https://doi.org/10.1371/journal.pone.0265746

Garrett, L., Sridhar, D., & Frenk, J. (2021). International cooperation during the influenza A(H1N1) pandemic of 2009: A critical assessment. *Foreign Affairs*, 90(4), 104–116.

Gaucherand, L., Porter, B. K., Levene, R. E., Price, E. L., Schmaling, S. K., Gaglia, M. M., & Rycroft, C. H. (2023). The influenza A virus endoribonuclease PA-X usurps host mRNA processing machinery to limit host gene expression. *Nature Microbiology*, 8(4), 645–660. https://doi.org/10.1038/s41564-023-01354-6

Gerdil, C. (2023). The annual production cycle for influenza vaccine. *Vaccine*, 21(16), 1776–1779. https://doi.org/10.1016/S0264-410X(03)00071-9

Gray, G. C., McCarthy, T., Capuano, A. W., Setterquist, S. F., & Alavanja, M. C. (2021). Evidence for avian influenza A infections among Iowa's agricultural workers. *Emerging Infectious Diseases*, 14(8), 1289–1291. https://doi.org/10.3201/eid1408.071589

Greene, S. E., Taubenberger, J. K., & Morens, D. M. (2022). The 1977 H1N1 influenza virus reappearance: Case for laboratory escape. *mBio*, 13(2), e03267-21. https://doi.org/10.1128/mbio.03267-21

Gubareva, L. V., Besselaar, T. G., Daniels, R. S., Fry, A., Gregory, V., Huang, W., & Hay, A. (2022).

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2016–2017. *Journal of Infectious Diseases*, 217(5), 731–741. https://doi.org/10.1093/infdis/jix642

Hale, B. G., Knebel, A., Bottermann, M., & Barclay, W. S. (2020). The multifunctional NS1 protein of influenza A viruses. *Journal of Virology*, 82(11), 5231–5241. https://doi.org/10.1128/JVI.00016-08

Hasegawa, S., Matsushige, T., Inoue, H., Shirabe, K., Fukuda, K., & Ichiyama, T. (2023). Acute necrotizing encephalopathy associated with influenza A infection. *Pediatrics*, 135(2), e1065–e1072. https://doi.org/10.1542/peds.2014-1784

Hayden, F. G., Sugaya, N., Hirotsu, N., Lee, N., de Jong, M. D., Hurt, A. C., & Ishida, T. (2021). Baloxavir marboxil for uncomplicated influenza in adults and adolescents. *New England Journal of Medicine*, 379(10), 913–923. https://doi.org/10.1056/NEJMoa1716197

Heikkinen, T., Silvennoinen, H., Peltola, V., Ziegler, T., Vainionpää, R., Vuorinen, T., & Heinonen, S. (2022). Burden of influenza in children in the community. *Pediatric Infectious Disease Journal*, 41(2), 121–125. https://doi.org/10.1097/INF.0b013e318258775d

Ho, C. W., & Gostin, L. O. (2023). The social determinants of pandemic influenza preparedness in Africa. *Journal of the American Medical Association*, 306(23), 2617–2618. https://doi.org/10.1001/jama.2011.1855

Imai, M., Watanabe, T., Hatta, M., Das, S. C., Ozawa, M., Shinya, K., & Kawaoka, Y. (2023). Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. *Nature*, 486(7403), 420–428. https://doi.org/10.1038/nature10831

Ison, M. G., Portsmouth, S., Yoshida, Y., Shishido, T., Mitchener, M., Tsuchiya, K., & Hayden, F. G. (2022). Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza: A randomized, placebo-controlled trial. *Journal of Infectious Diseases*, 221(11), 1898–1907. https://doi.org/10.1093/infdis/jiz647

Jackson, M. L., & Nelson, J. C. (2022). The test-negative design for estimating influenza vaccine effectiveness. *Vaccine*, 31(17), 2165–2168. https://doi.org/10.1016/j.vaccine.2013.02.053

Jackson, M. L., France, A. M., Hancock, K., & Schmier, J. (2021). Serologically confirmed household transmission of 2009 pandemic influenza A (H1N1) virus during the first pandemic wave. *Pediatrics*, 127(4), e1041–e1047. https://doi.org/10.1542/peds.2010-2186

Jackson, C., Vynnycky, E., Hawker, J., Olowokure, B., & Mangtani, P. (2023). School closures and influenza: Systematic review of epidemiological studies. *Health Economics*, 22(10), 1193–1205. https://doi.org/10.1002/hec.2876

Jagger, B. W., Wise, H. M., Kash, J. C., Walters, K. A., Wills, N. M., Xiao, Y. L., & Digard, P. (2021). An overlapping protein-coding region in influenza A virus segment 3 modulates the host response. *Science*, 337(6091), 199–204. https://doi.org/10.1126/science.1222213

Kandeel, A., Manoncourt, S., Abd el Kareem, E., Mohamed Ahmed, A. N., El-Refaie, S., Essmat, H., & El-Sayed, N. (2020). Zoonotic transmission of avian influenza virus (H5N1), Egypt, 2006–2009. *Emerging Infectious Diseases*, 16(7), 1101–1107. https://doi.org/10.3201/eid1607.091695

Kanekiyo, M., Joyce, M. G., Gillespie, R. A., Gallagher, J. R., Andrews, S. F., Yassine, H. M., & Graham, B. S. (2023). Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. *Nature*, 566(7745), 557–561. https://doi.org/10.1038/s41586-019-1032-7

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

Kash, J. C., Walters, K. A., Kindrachuk, J., Baxter, D., Scherler, K., Janosko, K. B., & Taubenberger, J. K. (2020). Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease. *Science Translational Medicine*, 12(574), eabb4263. https://doi.org/10.1126/scitranslmed.abb4263

Kayali, G., El-Shesheny, R., Kutkat, M. A., Bagato, O., Mostafa, A., Ducatez, M. F., & Ali, M. A. (2022). Continuing threat of influenza (H5N1) virus circulation in Egypt. *Journal of Virology*, 86(5), 2432–2435. https://doi.org/10.1128/JVI.06304-11

Kelly, P. M., Kotsimbos, T., Reynolds, A., & Streeton, C. (2022). Clinical and epidemiological features of pandemic (H1N1) 2009 in Victoria, Australia. *Medical Journal of Australia*, 192(11), 637–640. https://doi.org/10.5694/j.1326-5377.2010.tb03655.x

Klobasa, F., Habe, F., & Dauber, M. (2020). Biosafety and biosecurity in veterinary laboratories handling zoonotic agents. *Biologicals*, 38(3), 345–351. https://doi.org/10.1016/j.biologicals.2010.02.003

Kochs, G., Garcia-Sastre, A., & Martinez-Sobrido, L. (2021). Multiple anti-interferon actions of the influenza A virus NS1 protein. *Journal of Virology*, 81(13), 7011–7021. https://doi.org/10.1128/JVI.02581-06

Kolpe, A. B., Schepens, B., Fiers, W., & Saelens, X. (2022). M2-based influenza vaccines: Recent advances and clinical potential. *Expert Review of Vaccines*, 16(2), 123–136. https://doi.org/10.1080/14760584.2017.1240041

Kwong, J. C., Schwartz, K. L., Campitelli, M. A., Chung, H., Crowcroft, N. S., Karnauchow, T., & Gubbay, J. B. (2021). Acute myocardial infarction after laboratory-confirmed influenza infection. *New England Journal of Medicine*, 378(4), 345–353. https://doi.org/10.1056/NEJMoa1702090

Lafond, K. E., Nair, H., Rasooly, M. H., Valente, F., Booy, R., & Rahman, M. (2023). Global role and burden of influenza in pediatric respiratory hospitalizations, 1982–2012: A systematic analysis. *Bulletin of the World Health Organization*, 94(2), 113–128. https://doi.org/10.2471/BLT.15.157784

Lee, B. Y., Brown, S. T., Korch, G. W., Cooley, P. C., Zimmerman, R. K., Wheaton, W. D., & Burke, D. S. (2021). A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. *Medical Decision Making*, 31(2), 224–241. https://doi.org/10.1177/0272989X10386131

Lewis, N. S., Russell, C. A., Langat, P., Anderson, T. K., Berger, K., Bielejec, F., & Smith, G. J. (2021). The global antigenic diversity of swine influenza A viruses. *PLoS Pathogens*, 12(11), e1006076. https://doi.org/10.1371/journal.ppat.1006076

Lin, Y., Wharton, S. A., Whittaker, L., Dai, M., Ermetal, B., Lo, J., & Daniels, R. S. (2022). The characteristics and antigenic properties of recently emerged subclade 3C.3a and 3C.2a human influenza A(H3N2) viruses passaged in MDCK cells. *Cell*, 167(2), 482–492. https://doi.org/10.1016/j.cell.2016.08.037

Lopez-Gatell, H., Alpuche-Aranda, C. M., Hernandez-Avila, M., & Santos-Preciado, J. I. (2023). The 2009 influenza pandemic in Mexico: Experience and lessons. *Salud Pública de México*, 52(2), 97–103. https://doi.org/10.1590/S0036-36342010000200001

Ma, W., Kahn, R. E., & Richt, J. A. (2022). The pig as a mixing vessel for influenza viruses: Human and veterinary implications. *Veterinary Microbiology*, 140(3–4), 361–372. https://doi.org/10.1016/j.vetmic.2009.08.015

Marlowe, E. M., Novak-Weckley, S. M., & Leber, A. L. (2021). Multicenter evaluation of the Xpert Xpress Flu/RSV assay. *Journal of Clinical Microbiology*, 55(1), 50–58. https://doi.org/10.1128/JCM.01678-16

McAullay, D., Strobel, N. A., & Marriott, R. (2023). Improving Aboriginal and Torres Strait Islander health: A systematic review of the effectiveness of community-based interventions. *Medical Journal of Australia*, 218(8), 369–374. https://doi.org/10.5694/mja2.51964

McElhaney, J. E., Kuchel, G. A., Zhou, X., Swain, S. L., & Haynes, L. (2023). T-cell immunity to influenza in older adults: A key research gap. *Journal of Infectious Diseases*, 218(suppl_1), S1–S5. https://doi.org/10.1093/infdis/jiy266

Mena, I., Nelson, M. I., Quezada-Monroy, F., Dutta, J., Cortes-Fernández, R., Lara-Puente, J. H., & García-Sastre, A. (2022). Origins of the 2009 H1N1 influenza pandemic in swine in Mexico. *PLoS Pathogens*, 12(8), e1005841. https://doi.org/10.1371/journal.ppat.1005841

Meyer, A. G., Wilke, C. O., & Woods, R. J. (2022). Predicting influenza A virus host range transitions. *Nature Ecology & Evolution*, 3(2), 236–244. https://doi.org/10.1038/s41559-018-0781-2

Moncla, L. H., Zhong, G., Nelson, C. W., Dinis, J. M., Mutschler, J., Hughes, A. L., & Bedford, T. (2021). Selective bottlenecks shape evolutionary pathways taken during mammalian adaptation of a 1918-like avian influenza virus. *Cell Host & Microbe*, 19(2), 169–180. https://doi.org/10.1016/j.chom.2016.01.011

Morgan, O. W., Bramley, A., Fowlkes, A., Freedman, D. S., Taylor, T. H., Gargiullo, P., & Schrag, S. (2022). Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. *Clinical Infectious Diseases*, 55(3), 326–331. https://doi.org/10.1093/cid/cis329

Nair, H., Brooks, W. A., Katz, M., Roca, A., Berkley, J. A., & Madhi, S. A. (2021). Global burden of respiratory infections due to seasonal influenza in young children: A systematic review and meta-analysis. *Bulletin of the World Health Organization*, 89(12), 856–864. https://doi.org/10.2471/BLT.11-088187

Nelson, M. I., Vincent, A. L., Kitikoon, P., Holmes, E. C., & Gramer, M. R. (2023). Evolution of influenza A viruses in swine. *Cold Spring Harbor Perspectives in Medicine*, 13(2), a038679. https://doi.org/10.1101/cshperspect.a038679

Neher, R. A., Bedford, T., Daniels, R. S., Russell, C. A., & Shraiman, B. I. (2023). Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses. *Proceedings of the National Academy of Sciences*, 120(12), e2212877120. https://doi.org/10.1073/pnas.2212877120

Nunes, M. C., & Madhi, S. A. (2023). Influenza vaccination during pregnancy. *Vaccine*, 35(37), 5137–5142. https://doi.org/10.1016/j.vaccine.2017.08.039

Ortiz, J. R., Perut, M., Dumolard, L., Wijesinghe, P. R., Jorgensen, P., Ropero, A. M., & Bresee, J. (2022). A global review of national influenza immunization policies: Analysis of the 2014 WHO/UNICEF Joint Reporting Form on immunization. *Bulletin of the World Health Organization*, 94(9), 663–671. https://doi.org/10.2471/BLT.16.171447

Oshansky, C. M., Gartland, A. J., Wong, S. S., Jeevan, T., Wang, D., Roddam, P. L., & Thomas, P. G. (2023). Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load. *Journal of Immunology*, 193(2), 822–831. https://doi.org/10.4049/jimmunol.1400385

Pebody, R., Warburton, F., Ellis, J., Andrews, N., Potts, A., Cottrell, S., & Zambon, M. (2021). Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. *Eurosurveillance*, 21(38), 30348. https://doi.org/10.2807/1560-7917.ES.2016.21.38.30348

Peiris, J. S., de Jong, M. D., & Guan, Y. (2021). Avian influenza virus (H5N1): A threat to human health.

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

Clinical Microbiology Reviews, 20(2), 243–267. https://doi.org/10.1128/CMR.00037-06

Pierce, M., Kurinczuk, J. J., Spark, P., Brocklehurst, P., Knight, M., & UKOSS. (2021). Perinatal outcomes after maternal 2009/H1N1 infection: National cohort study. *Clinical Infectious Diseases*, 52(2), 238–243. https://doi.org/10.1093/cid/ciq081

Pillet, S., Aubin, É., Trépanier, S., Bussière, D., Dargis, M., Poulin, J. F., & Landry, N. (2021). A plant-derived quadrivalent virus-like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. *Vaccine*, 34(4), 514–520. https://doi.org/10.1016/j.vaccine.2015.11.073

Preaud, E., Durand, L., Macabeo, B., Farkas, N., Sloesen, B., Palache, A., & Samson, S. I. (2022). Annual public health and economic benefits of seasonal influenza vaccination: A European estimate. *Human Vaccines & Immunotherapeutics*, 10(8), 2275–2285. https://doi.org/10.4161/hv.29269

Putri, W., Muscatello, D. J., Stockwell, M. S., & Newall, A. T. (2021). Economic burden of seasonal influenza in the United States. *Vaccine*, 36(27), 3960–3966. https://doi.org/10.1016/j.vaccine.2018.05.057

Rasmussen, S. A., Jamieson, D. J., & Bresee, J. S. (2022). Pandemic influenza and pregnant women. *Emerging Infectious Diseases*, 14(1), 95–100. https://doi.org/10.3201/eid1401.070667

Rossignol, J. F., La Frazia, S., Chiappa, L., Ciucci, A., & Santoro, M. G. (2021). Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. *Journal of Virology*, 83(22), 11892–11900. https://doi.org/10.1128/JVI.01217-09

Russell, C. A., Kasson, P. M., Donis, R. O., Riley, S., Dunbar, J., Rambaut, A., & Burke, D. F. (2023). Improving pandemic influenza risk assessment. *Nature*, 507(7490), 57–61. https://doi.org/10.1038/nature13035

Schwartz, J. L., Gellin, B. G., Mahmoud, A., & Evans, G. (2022). Accelerating development of vaccines against pandemic influenza. *New England Journal of Medicine*, 362(20), 1926–1927. https://doi.org/10.1056/NEJMe1004575

Schnell, J. R., & Chou, J. J. (2020). Structure and mechanism of the M2 proton channel of influenza A virus. *Nature*, 451(7178), 591–595. https://doi.org/10.1038/nature06531

Sims, L. D. (2021). Lessons learned from Asian H5N1 outbreak control. *Avian Diseases*, 51(1), 174–181. https://doi.org/10.1637/7453-101006R.1

Smith, G. J., Bahl, J., Vijaykrishna, D., Zhang, J., Poon, L. L., Chen, H., & Guan, Y. (2021). Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. *Nature*, 459(7250), 1122–1125. https://doi.org/10.1038/nature08182

Smith, R. D. (2023). Responding to global infectious disease outbreaks: Lessons from SARS on the role of risk perception, communication and management. *Social Science & Medicine*, 63(12), 3113–3123. https://doi.org/10.1016/j.socscimed.2006.08.004

Snelling, T. L., Carapetis, J. R., & Gadil, E. (2021). Aboriginal and Torres Strait Islander children and the pandemic H1N1/09 influenza. *Medical Journal of Australia*, 192(11), 617–618. https://doi.org/10.5694/j.1326-5377.2010.tb03655.x

Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., & Zambon, M. (2023). Cellular immune correlates of protection against symptomatic pandemic influenza. *Nature Medicine*, 19(10), 1305–1312. https://doi.org/10.1038/nm.3350

Sterlin, D., Mathian, A., Miyara, M., Mohr, A., Anna, F., Claër, L., & Gorochov, G. (2021). IgA dominates the early neutralizing antibody response to SARS-CoV-2. *Science Translational Medicine*, 13(577), eabd2223. https://doi.org/10.1126/scitranslmed.abd2223

Sukumaran, L., McCarthy, N. L., Kharbanda, E. O., Vazquez-Benitez, G., Lipkind, H. S., Jackson, L. A., & Naleway, A. L. (2023). Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy. *Obstetrics & Gynecology*, 126(5), 1069–1074. https://doi.org/10.1097/AOG.0000000000001555

Tate, M. D., Schilter, H. C., Brooks, A. G., & Reading, P. C. (2021). Responses of mouse airway epithelial cells and alveolar macrophages to virulent and avirulent strains of influenza A virus. *Virology Journal*, 8, 351. https://doi.org/10.1186/1743-422X-8-351

Tokars, J. I., Olsen, S. J., & Reed, C. (2022). Seasonal incidence of symptomatic influenza in the United States. *Clinical Infectious Diseases*, 66(10), 1511–1518. https://doi.org/10.1093/cid/cix1060

Turner, D. L., Bickham, K. L., Thome, J. J., Kim, C. Y., D'Ovidio, F., Wherry, E. J., & Farber, D. L. (2023). Lung niches for the generation and maintenance of tissue-resident memory T cells. *Mucosal Immunology*, 7(3), 501–510. https://doi.org/10.1038/mi.2013.67

Uscher-Pines, L., Harris, K. M., Burns, R. M., & Meisel, Z. F. (2021). Priority setting in a pandemic: The case of the 2009 H1N1 vaccine. *Health Security*, 13(4), 225–233. https://doi.org/10.1089/hs.2014.0086

Uyeki, T. M., Bernstein, H. H., Bradley, J. S., Englund, J. A., File, T. M., Fry, A. M., & Pavia, A. T. (2022). Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. *Clinical Infectious Diseases*, 68(6), e1–e47. https://doi.org/10.1093/cid/ciy866

Valery, P. C., Wenitong, M., Clements, V., Sheel, M., McMillan, M., & O'Grady, K. A. (2022). Acute respiratory infections in Torres Strait Islander children and adults: A narrative review. *Medical Journal of Australia*, 216(10), 534–540. https://doi.org/10.5694/mja2.51507

van de Sandt, C. E., Kreijtz, J. H., & Rimmelzwaan, G. F. (2021). Evasion of influenza A viruses from innate and adaptive immune responses. *Viruses*, 4(9), 1438–1476. https://doi.org/10.3390/v4091438

Verhagen, J. H., Fouchier, R. A., & Lewis, N. (2022). Highly pathogenic avian influenza viruses at the wild–domestic bird interface in Europe: Future directions for research and surveillance. *Viruses*, 13(2), 212. https://doi.org/10.3390/v13020212

Weber, M., Gawanbacht, A., Habjan, M., Rang, A., Borner, C., Schmidt, A. M., & Weber, F. (2022). Incoming RNA virus nucleocapsids containing a 5′-triphosphorylated genome activate RIG-I and antiviral signaling. *Cell Host & Microbe*, 13(3), 336–346. https://doi.org/10.1016/j.chom.2013.02.009

Wolfe, M. K., Archana, A., Catoe, D., Coffman, M. M., Dorevich, S., Graham, K. E., & Boehm, A. B. (2023). Scaling of SARS-CoV-2 RNA in settled solids from multiple wastewater treatment plants to compare incidence rates of laboratory-confirmed COVID-19 in their sewersheds. *Environmental Science & Technology Letters*, 8(9), 398–404. https://doi.org/10.1021/acs.estlett.1c00184

Wu, N. C., & Wilson, I. A. (2022). Structural biology of influenza hemagglutinin: An amaranthine adventure. *Current Opinion in Virology*, 44, 191–200. https://doi.org/10.1016/j.coviro.2020.10.004

Xue, K. S., Stevens-Ayers, T., Campbell, A. P., Englund, J. A., Pergam, S. A., Boeckh, M., & Bloom, J. D. (2023). Parallel evolution of influenza across multiple spatiotemporal scales. *eLife*, 6, e26875.

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

https://doi.org/10.7554/eLife.26875

Yang, J., Liu, S., Du, L., Jiang, S. (2023). A dry powder formulation of laninamivir octanoate is effective and safe for inhalation treatment of influenza. *Antiviral Research*, 137, 141–146. https://doi.org/10.1016/j.antiviral.2016.11.021

Zimmer, S. M., & Burke, D. S. (2021). Historical perspective—Emergence of influenza A (H1N1) viruses. *New England Journal of Medicine*, 361(3), 279–285. https://doi.org/10.1056/NEJMra0904322

Zost, S. J., Parkhouse, K., Gumina, M. E., Kim, K., Diaz Perez, S., Wilson, P. C., & Hensley, S. E. (2021). Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. *Cell*, 171(7), 1734–1745. https://doi.org/10.1016/j.cell.2017.10.040